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S U M M A R Y  
 
Genetic counselling is a complex process that helps people to understand and adopt medical, 
psychological and genetic aspects of the disease and enable them to make an appropriate decision.  
In this framework, we revisited all the existing models for decision-making and suggested their use in the 
process of genetic counselling, which may lead to more equitable and more favourable outcomes. Also, 
Donabedian's (Structure-Process-Outcome) model for the development of key performance indicators was 
applied to assess the quality in the process of genetic counselling.   
Quality indicators at SPO model in the process of genetic counselling were proposed. The social, 
economic and humanistic outcomes have also been identified.  
All defined quality indicators together represent a framework for monitoring, evaluation and 
continuous improvement of the process of genetic counselling. Although the new medical services of 
genetic counselling tend to be developed as a powerful multidisciplinary field, the implementation of 
quality management model will certainly help the development of collaborative practice. 
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Genetic counselling (GC) is a complex process 
of advising patients or relatives about the risk, 
consequences and the nature of inherited disorders. 
It is assosiated with different genetic researches, and 
involves pre-test counselling as well as post-test 
counselling to enable the individuals to face the 
research results and to take appropriate decisions 
with the right information. 
Genetic testing before the start of drug 
therapy in order to predict their likely response is 
crucial in achieving the desired effect. Genetic 
counselling aims to encourage people to decide on 
testing, to assist in a common understanding of ge-
netic diseases, and to provide psychological support 
after testing. It has a role before, during and after the 
test (1). More professionals should be involved due 
to the complexity of genetic counselling. Associated 
engagement of pharmacists and genetic counsellors 
can assist physicians in understanding and inter-
preting the results of pharmacogenetic testing. 
Pharmacists can use their knowledge from pharma-
cokinetics and pharmacodynamics and help phy-
sicians to choose the appropriate drug or proper 
dosage, and to avoid possible adverse reactions. 
They are also included in patients’ education, 
recommending testing and reporting on patients’ 
test results. However, their knowledge of genetics is 
not enough, and therefore genetic counsellors must 
be involved in dealing with specific issues for 
genetic testing. 
Delivery of pharmacogenetic services by phar-
macists or genetic counsellors can be conducted in 
person, electronically (e.g. by providing recommen-
dations to physicians with checking patients’ 
laboratory analyses or electronic health records), or 
by phone (providing advice to patients or phy-
sicians) (2). 
It is important to achieve and maintain high 
quality in genetic counseling. It largely depends on 
the health professionals who participate in 
counseling. If doctors in primary health care or 
surgeons are involved, it would be necessary to be 
qualified in the field of genetics. Quality can be 
increased by improving the training of genetics for 
medical students and physicians with providing 
information about the existence of genetic coun- 
seling and potential problems. Genetic counsellors  
 
 
should have some sort of accreditation, which 
includes appropriate training and exams (3). For 
pharmacists, the introduction of pharmacogenetics 
into the curriculum is recommended, as well as pro-
viding access to educational programs in pharma-
cogenetics that will help them to make appropriate 
use of laboratory diagnostics (2).  
Increasing demand for genetic counseling in 
recent years leads to the following results: 1) search 
for quality genetic counselling; 2) growing aware-
ness that our knowledge of the genetic counseling 
services is poor (3). 
 
Models of decision-making in genetic 
counseling 
 
The question that is often asked is whether the 
genetic counseling can be seen as part of regular 
healthcare interaction or as a separate discipline? 
The research carried out on this subject has shown 
similarities between communication in the process of 
genetic counseling and other healthcare interactions, 
challenging the claim that is regarded as a separate 
service due to the large presence of bioethics in this 
field.  
A patient-centred approach is often im-
plemented in the interactions of healthcare and even 
genetic counseling is not an exception. Family 
involvement was shown as a significant help to the 
patient. 
Communication and exchange of information 
are very important in establishing a good rela-
tionship. Difficulties in genetic counseling as well as 
other interactions are the lack of alignment between 
what the patient expects to hear and what the 
healthcare professional carries out.  
Shared decision-making is an integral part of 
all healthcare services, and it is the preferred model 
for both genetic and non-genetic healthcare 
professionals, as well as providing emotional sup-
port.  
Geneticists have more specialized knowledge 
of this field than other non-genetic professionals. 
Association with  non-genetic professionals can 
significantly contribute to the discipline of genetic 
counselling, because the introduction of similar 
concepts and methodologies can help genetic coun-
sellors to expand various possibilities of information 
exchange with other professionals involved in the 
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testing and improvement of medical communi-
cations (4). 
There are several models of decision-making 
in health care. Among them are observed differences 
in the objectives of interaction between counsellors 
and patients, the duties and responsibilities of 
counsellors, the role of patient and the concept of 
patient autonomy. We shall evaluate these models 
and recommend their use in the process of genetic 
counseling. 
The first is paternalistic model, where the 
dominant role of clinicians who can make the best 
decision for a patient is presented. This model is 
described as a unilateral decision unrelated to the 
patient's wishes and values. However, sometimes it 
is necessary for physicians to make a decision that is 
in the best interest of their patient without his prior 
consultation. As has been known since the time of 
Hippocrates, a doctor always has a goal and that is 
the benefit of his patient (5).  
The second model is known as ″autonomous″ 
or ″patient-centred″. In this model, a clinician com-
municates to a patient available options and relevant 
medical information, but the patient select their ed c 
x own treatment. Patient-centred care is defined as: 
″The experience of transparency (to the extent that 
the informed, individual patient desires it), individ-
ualization, recognition, respect, dignity, and choice 
in all matters, without exception, related to one’s 
person, circumstances, and relationships in health-
care″. Knowledge is a transfer from a patient to a 
provider (6).  
The following is shared decision-making 
(SDM), which is a collaborative process where a 
clinician/counsellor and a patient communicate 
taking into account the most relevant evidence in 
making appropriate decisions. This process aims to 
increase the involvement of all participants in the 
chain of decision-making at all levels (7). 
Finally, there is collaborative decision-making 
(CDM) in which both sides “work together, es-
pecially in a joint intellectual effort“. While coun-
sellors know more and have experience with medical 
issues, patients have their own and life experiences. 
Patients also may possess medical knowledge which 




Genetic counselling raises special ethical 
issues related to confidentiality and privacy pro-
tection. Information about the individual, family 
history, carrier status, risk of genetic disease can be 
stigmatising and hence needs to be kept confidential. 
Most of the time, the patient is concerned about the 
future reproductive or personal health risks. The 
counsellor has to make an assessment by obtaining 
family history and by analysing the pedigree chart to 
provide information regarding the treatment op-
tions, preventive strategies, including reproductive 
options and the financial and social implications.  
Ethical issues to take into consideration when 
providing GC: 
a) respect for patient autonomy;  
b) respect for patient confidentiality; 
c) respect for patient privacy; 
d) right to information and the right  to make 
his/her own decisions; 
e) non-maleficence, which is defined as one's 
“duty to minimize or prevent the infliction of harm 
on individuals and families”; 
f) beneficence, or taking action to help others 
and prevent harm, both physical and mental; 
g) justice, which requires that services must be 
distributed fairly to those in need; 
h) veracity, the duty to disclose information or 
to be truthful.  
 
Donabedian's model as a framework of 
quality in health care  
 
Avedis Donabedian introduced the basic 
concept of quality health care. This model describes 
three fundamental parts of health care and their 
mutual relationship.  
Firstly, structure represents the methods of 
providing health care that refers to the appropriate 
facilities and equipment, adequate number of qual-
ified healthcare professionals and their diversity. 
Also, it is referred to organizational characteristics 
such as the organization of personnel, training, the 
methods of payment of health care, as well as ad-
ministrative structure and programs. Structure can 
sometimes be a major determinant of the quality 
assessment of health system. Some features of the 
structure can be easily monitored. They are more 
stable and simpler for documenting. But, on the 
other hand, numerous variations in the structure are 
less related to variations in outcomes, because in 
practice it is usually not a good setting of the rela-
tionship between structure and process and struc-
ture and outcome. 
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Secondly, the process means the activities in 
the provision of health care that includes: health 
promotion, disease prevention, treatment, reha-
bilitation and patient education. It is very important 
to apply the appropriate values and standards to be 
used in the assessment. Monitoring process is 
facilitated by current events and easy collection of 
patient data through observation, examination or 
from medical records. Although the quality of 
providing health care is often identified with the 
quality of health care, it is necessary also to take into 
account the established connection between process 
and outcome.  
Finally, the third determinant outcome de-
scribes a change in a person's health (desired or not), 
that can be connected with health care. In the 
evaluation of patient attitudes and satisfaction, it is 
sometimes difficult to measure outcomes as they are 
not expressed quickly. It is often difficult to make a 
connection between the previous health care and 
resulting outcomes. Donabedian said that measuring 
the quality of health care services is not accurate, 
also it is not complete, and it should have flexibility 
in interpreting the outcome, which cannot be consid-
ered separately from the structures and processes. 
It is important to determine the impact be-
tween these major components: the direct influence 
of structure on a process and the process on the 
result. Also, outcomes provide feedback to the 
structure and process to define the changes that are 
needed to be applied. 
Donabedian's model has undergone various 
changes in recent years, which makes it specific for 
the implementation of new services in modern 





The aims of this paper are: (a) reviewing the 
existing models of decision-making at health care 
services that could be applied for the counselling 
phase of genetic counselling service, (b) identifi-
cation for QM for the counselling phase in GCS (c) 
the development of quality management indicators 




We used manual documentation analysis to 
find models of decision˗making in health care and 
quality indicators by Donabedian`s model with the 
possibility of adapting the application in the process 
of genetic counselling. Given that the interest of 
research was predominantly in the literal wording 
and terminology, manual method is shown in Table 
1. 
The process of analysis included several steps. The 
first step was the selection of documents including a 
comparison with other framework. In this step, we 
considered all the existing models of decision-
making and documents on the topic of Donabedian's 
model. In the next step we dealt with the reading 
and interpretation of works in order to determine the 
purpose and objectives and the understanding of the 
content. Then we considered the terminology 
characteristic of the objectives previously set and the 
generalization of the terms by searching key words 
or phrases. In the last step, we  evaluated models 
and recommended their use in the genetic coun-
selling. Also, we proposed quality indicators at the 
structure˗process˗outcome model in the process of 
genetic counselling. 
 
Table 1. The stages with  considerations of manual documentation analysis 
 
Manual documentation analysis Considerations 
Stage 1 
 
The selection of documents and 
comparison with other frameworks 
The decision˗making models in health care and 
quality indicators by Donabedian`s model 
Stage 2 Reading and "interpretation" The purpose and objectives of the documents 
Stage 3 Searching by key words or phrases The terminology characteristic of the set objectives 
and generalizability of terms 
Stage 4 Recording and reconciliation of findings Proposing the application of models and quality 
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RESULTS 
 
We collected four models from the literature 
concerning the decision-making in health care 
settings as presented in Table 2. The first analyzed 
model was paternalistic model, where the counsellor 
has the parental role and he decides what is the best 
for the patient. The counsellor has obligations to use 
their knowledge in identifying the medical condition 
of the patient and to find a suitable test that would 
allow the diagnosis, drug selection and dosing, 
providing selected information to encourage patients 
to make a decision about testing with the goal of pro- 
 
 
viding the patients’ well-being. In an extreme sit-
uation, the counsellor may inform the patient about 
the beginning of the process without the patient's 
response. Also, the counsellor has a duty to put the 
interest of the patient above his personal, and to seek 
the assistance of another professional if they do not 
possess the required appropriate knowledge.  
The concept of patient autonomy in this 
model refers to the assent of the patient at the time, 
or later when the counsellor determines what is the 
best for the patient. 
 
Table 2. The models of decision-making in health care and GC feasibility [adapted from reference 5]. 
 
Model Provider Patient Knowledge flow Objective Feasibility 
to GC 
Paternalistic Directive Passive One-way knowledge 
transfer: provider to patient 
Patient compliance Low 
Autonomous Receptive Directive One-way knowledge 
transfer: patient to provider 




















Knowledge builds through 
shared learning 
Optimal action High 
 
 
It is well-known that the paternalistic model is 
suited to emergency situations where the waiting 
time for the patient consent to participate in testing 
may adversely affect his health. Probably, for 
counsellors and patients, this will not be an ideal 
model for counsellor-patient relationship.  
In patient-centred model, the information is 
directed from the patient to the counsellor. Of 
course, counsellor must inform the patient about 
their medical condition and disease, the nature of 
genetic testing, the benefits and risks of the same and 
they must resolve any ambiguity or the lack of 
knowledge. 
In this model, the patient's values are well-
known and defined. The values of  the counsellors 
are not involved, due to their role is understand the 
patient's values. 
Counsellors as tehnical experts have an obli-
gation to provide truthful information, to maintain 
competence in their area, and certainly to consult 
with other health care professionals in case of  inade-
quate knowledge. The concept of patient autonomy 
is based on the fact that patient controls the whole 
medical decision-making. 
The following model included in the review is 
shared decision-making, where great importance is 
emphasized for both sides to framework SDM 
application in the process of genetic counselling. 
With respect to the focus of the patient's health, there 
are justifiable reasons for including genetic coun-
sellors in this process by providing evidence that 
will be of direct medical benefit to the patient, with 
respecting his or her ultimate autonomy. 
This framework would allow geneticists to 
communicate complex information on risks and 
uncertainties to patients. It can also help the coun-
sellor to provide clinical recommendations that are 
significant by giving theirexpert opinion. SDM can 
be helpful in diagnostic pathways when patients are 
faced with discomfort, anxiety, pain and other 
conditions.  
Another important aspect in this process is the 
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implication of genetic information to other family 
members. This is very important for them to be able 
to organize their lives, to plan reproduction and to 
control the early signs of complications that can be 
cured if detected in time. Counsellors should sup-
port those patients who wish to transfer genetic 
information that can be useful, even by giving them 
a bit of persuading to do. 
The decision-making process in this compre-
hensive discipline moved to a collaborative mode. 
The collaborative decision-making combines the 
talents and experiences of all individuals. While coun- 
sellors know more and have experience with medical 
issues, patients have their own and life experiences. 
Patients also may possess medical knowledge which 
should be taken into account.  
 
What is the philosophy of CDM?  
 
• Embraces partnership;  
• Combines the talents and the experience of 
ALL individuals and organisations;  
• Shares values and preferences; 









The role of the counsellor is to inform the 
patient about the reasons for testing, and what to 
expect regarding the process of pharmacogenetic 
testing. Counsellor and patient together formulate 
decisions on treatment.   
This framework allows the counsellor to shape 
medical issues and to ensure their participation in 
the health management process of patients with 
clearly defined and emphasized responsibilities and 
boundaries. The patients must have an abandoned 
place for reconsideration of their decision.  
Collaborative decision-making model unlike 
other models focuses on the highest priorities re-
garding health problems. The implementation of this 
model will allow patient to solve medical problems 
in the context of a much richer and more complex 
life (adapted from 8 and 5). Quality Management 
CDM in the Genetic Counseling Services is pres-
ented in Figure 1.  
 
Quality indicators in genetic counseling 
 
Donabedian's SPO model was a conceptual 
point for the research and development of key 
performance indicators for assessing the quality of. 
service in genetic counselling. In Table 3, theclassifi- 
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Table 3. The classification of key performance indicators for Genetic Counseling Services (GCS) 
 
 
cation of key performance indicators for monitoring, 
assessment and continuous improve-ment in genetic 
counselling were identified. 
 
Indicators of structure 
 
An enormous effort must be invested in 
ensuring the availability of genetic testing, following 
many countries of Europe and the United States and 
advocating for their commercial use, in order to 
select the appropriate drug specific for each patient, 
to shorten the time of treatment and to avoid patient 
suffering as well as his family and to reduce un-
necessary costs.  
The existence of a large number of various 
health professionals is essential for providing genetic 
counseling. It involves mutual cooperation of gen-
eral practitioners, medical geneticists, genetic nurses, 
pharmacists and genetic counsellors. The popular 
survey of health care professionals in terms of their 
priorities in the selection of appropriate health care 
professionals for providing genetic counselling have 
shown that primary care has the primary role. In 
terms of the selection of the required test, they gave 
an advantage to medical genetics. Still in the stage of 
making attempts, they had a great interest in paying 
attention to the proposed partnership between ge-
netic counsellors and pharmacists, and their benefits 
to all (10). 
These test results depend heavily on the 
expertise of health care professionals. With this re- 
gard, it is necessary to provide support for specific 
genetic courses and trainings and to enable them to 
access the electronic sources of information. A coop-
eration of European countries as well as an adapta-
tion of curricula are needed (11). 
The knowledge and understanding of the 
patient's need for genetic counseling and genetic 
testing is still at a low level. Patient education is 
crucial to realize that they have enough knowledge 
about the disease, then a potential risk for them-
selves and their families, and thus enable the avail-
able support, disease prevention and treatment 
needed.  
When asked a question about how they would 
like to be informed, whether through a computer 
program that contains all necessary pieces of in-
formation, or by genetic counselors, the opinions 
were divided. In terms of genetic counselors, they 
emphasized the advantage of personal discussion-
listening caution and compassion with their emo-
tional problems, considering options, saying what is 
important to know and supporting them. With com-
puter programs, patients see the benefits of learning 
tailored to their pace, better use of time and avoiding 
embarrassment (12). 
Payment for genetic counseling service has 
become a major problem that has seen strong growth 
in recent years. Proposal is to subsidize the cost by 
state as the number of health services, since ex-post 
payment cannot cover many procedures (3). 
 
 
S Structure indicators P Process indicators O  
Outcome 
indicators 
S.1  Information, availability and transparency for 
consumers on  GCS 
P.1 Standard operative procedures 
for the GCS 
O.1  Psychosocial 
support 
S.2  
Human Resources (the number of counsellors 
and the expertise of counsellors per GCS) 
P.2 





S.3  Equipment and facilities P.3 
The number of counseling 




S.4  The education of GCS members  P.4 
The number of positive 
decisions made per GCS 
O.4  Patient 
satisfaction 
S.5  Payment for GCS P.5 
The number of positive 
decisions made per patient 
O.5  The quality of 
life 
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Indicators of process 
 
Our reputed process of genetic counselling 
would include the following steps: 
1) Observing family history that covers all medical 
problems; 
2) Analyzing a family history of genetic and/or 
other birth defects; 
3) Assessing the risk of occurrence or recurrence 
genetic abnormalities in the family; 
4) Discussing its nature with emphasis on the 
inheritance factor; 
5) Pointing out the available options to reduce 
risk, including genetic testing; 
6) Discussing the benefits and risks of each 
possible option with paying due attention to 
the patient's understanding; 
7) Providing assistance in choosing the appro-
priate decisions for the patient and his family; 
8) Providing supportive counselling when it is 
needed; 
9) Assisting in carrying out testing; 
10) Documenting the process of counselling (adapt-
ed from the 13). 
 
Indicators of outcomes 
 
Genetic counsellors provide psychosocial 
support, show concern, empowerment and decision 
support, primarily in terms of patient benefits. 
Patients see it as encouraging, because by trans-
ferring experiences to counsellors, this enables them 
to cope with their problems. They stress the 
importance of long-term support, which are held by 
telephone or by other means, and the availability of 
genetic counsellors whenever is needed. 
In the process of genetic counseling, patients 
expect professionalism and the expertise of coun-
sellors. Patients emphasized the importance of 
providing information and transferring knowledge. 
Consideration of the outcome of genetic coun-
selling leads to the conclusion that facilitates com-
munication within family. Counsellors suggest the 
necessity of a family member to attend counseling in 
order to comprehend the family history as well as to 
show greater understanding and to be involved in 
the patient's thinking. They believe that it really 
means a lot to the patient (14). 
Given that this service is different from many 
medical services, it cannot point to a direct benefit to 
health. Measures that assess the health status and the 
quality of life are rarely used in genetic counseling, 
for example, they are used in cancer genetics. In this 
area, concern is significantly correlated with an 
increased anxiety and stress, and interferes with the 
usual function and health, that is especially pro-
nounced in case of positive family history (15). 
The ultimate outcome of the service provided, 
which is also of utmost importance, is patient’s satis-
faction. If patient’s expectations are met, the goal is 
achieved. 
 
Economic, clinical and humanistic outcomes 
(ECHO model) 
 
The Echo model represents the value of 
pharmaceutical services that combines traditional 
clinical outcomes with contemporary outcomes re-
lating to economic efficiency and quality. It views 
the service as pooling of their economic, social and 
humanistic outcomes. Safety and efficacy have not 
been more than only the essentials, but the im-
portance is given to the effect on the total health 
resource use, costs, and the quality of life. The Echo 
model should help the providers of health services in 
the planning, implementation and evaluation of its 
services from a wider point of view (16). 
Economic outcomes represent total costs 
(medical, non-medical and indirect) associated with 
treatment alternatives that are in balance with social 
and humanistic outcomes. The purpose of intro-
ducing the concept of pharmacogenomics was to 
identify a specific drug that can be safe, efficient and 
cost-effective for a patient. In compliance with lim-
ited healthcare budgets, it is necessary to consider 
that the best health interventions are applicable, 
useful for the patient and cost justified. Pharma-
cogenomic services showed a higher value in terms 
of benefits and costs compared to current interven-
tions (17). Two facts should be noted: 1. the costs of 
using pharmacogenetic tests are more expensive 
than the cost of the test; 2. they are related to the 
impacts on other health interventions such as 
managing drug side effects, blood tests, and others. 
The people responsible for the health budget will 
decide on the type of cost in proportion to the money 
they have. Then, the value associated with the pay-
ment of genetic counsellors and other health 
professionals involved was analyzed. Introduction of 
tests is intended to reduce side effects and to im-
prove better adherence by patients and consequent-
ly, a better quality of life. It is not easy for decision 
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makers to introduce pharmacogenetic testing due to 
a lot of things that must be taken into consideration. 
(18). The recommendation is to apply the cost-
effectiveness analysis in order to estimate the 
technical efficiency of an intervention. The cost-
effectiveness analysis is one of the most commonly 
used type of economic evaluation that compares 
similar therapeutic interventions in terms of their 
effects on the basis of the achieved cost per unit. This 
analysis in pharmacogenomics involves an assess-
ment of factors such as genetic testing, disease stage 
and treatment. Genetic testing would be cost 
effective in the following cases: 1. when a cheaper, 
alternative test for diagnosis is not available, the use 
of genetic tests that are highly sensitive and specific 
is presumed; 2. when it comes to diseases in which 
mortality is expected if left untreated; 3. when 
polymorphism prevails in the population, and 4. 
when a treatment involves significant costs or results 
that can be avoided by the genotype-individualized 
therapy. Pharmacogenomics is appropriate to be 
applied for diseases that require medication with 
narrow therapeutic range, with large inter-in-
dividual response, in which alternative methods of 
monitoring and treatment do not exist or are not 
available (19). It is necessary to understand the 
present situation in order to improve the cost 
analysis model in the future. Better methodological 
challenges are expected. Clinicians and people who 
make decisions regarding the allocation of resources 
for pharmacogenetic tests should have enough 
robust information on the benefits and costs of 
patients. Therefore, it is necessary to include genetic 
counsellors who will give the right and necessary 
information which will help the patient in making 
decisions regarding genetic testing and thus reduce 
unnecessary costs. The introduction of genetic 
counseling is a key step in pharmacogenetics. 
Clinical outcomes are medical events that 
occur as a result of disease or treatment. With 
emphasis on the benefit of pharmacogenetic tests, it 
is the potential reduction of adverse effects com-
pared to traditional methods. Some adverse reac-
tions, including serious ones such as morbidity and 
mortality caused by the genetic variation, can now 
be prevented. A modified dose or the dosage of the 
drug in patients who have a reduced capacity to 
metabolize due to genetic variability, will help in 
avoiding the adverse metabolic pathways. In the 
case of diseases where it is possible to take certain 
measures to protect patients from the harmful effects 
of the mutated gene, it is essential that a genetic 
counsellor monitors a relative of this person. In 
children with metabolic errors such as the genetic 
types of cretinism, phenylketonuria and galacto-
semia, it has previously been advised that treatment 
starts as soon as possible based on genotyping. 
Counselling is also necessary in case of a deficiency 
of G6PD, malignant hyperthermia, as well as in the 
deficiency of pseudo cholinesterase and other 
diseases, where the mutant individual must be pro-
tected against specific agents. Patients with hypertri-
glyceridemia and hypercholesterolemia should be 
warned about protective measures related to the 
cardiovascular system, while patients with con-
genital A1 - antitrypsin deficiency should be advised 
not to smoke. In these diseases, the significance of 
monitoring relatives is performed in order to pre-
vent adverse clinical outcomes (3). 
Humanistic outcomes represent the functional 
status or the quality of life. The importance of 
including genetic counsellors, with respect to their 
psychological impact on the genetic information 
received by patients, is emphasized. They are re-
flected in visible changes in the patient’s satisfaction 
with understandable information, the ability to 
work, social reintegration, avoiding undue stress 
and, above all, patients’psychological well-being. 
These outcomes help in the evaluation process of 
genetic counseling, if they are appropriate. Meeting 
the needs and priorities of patients are of vital 
importance for genetic counsellors. Patients need to 
talk about their needs in meetings with a counsellor 
so as their expectations could be met. The patient's 
attitudes and beliefs should be recognized in their 
speech, as well as feelings, whether they are feelings 
of guilt, stress, crying, loss of will and worthlessness. 
It is up to genetic counsellors to be good psychol-
ogists and it is one of the requirements they must 
meet. Patients will not be able to define their 
expectations if they do not understand the nature of 
counseling, or do not have the opportunity to 
consider the benefits of counseling. It has been 
proven that when they met their expectations 
regarding the provision of appropriate advice and 
security, the patients’ concern and anxiety were 
avoided. If patients are not sure that they have had a 
consultation process, they would not be able to 
assess whether it was necessary or not. Objectives 
and their explanations must be clearly indicated by 
the counsellor. The process that will indicate 
whether the patient understands the information 
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received and whether communication was under-
standable is necessary to exist. When these criteria 
are met, patients will be able to play the role of inter-




Genetic counseling is a relatively new medical 
service with a tendency to be widely applied. This 
audit has demonstrated that the existing models of 
decision-making are applicable for genetic coun-
selling services. It is shown that better outcomes are 
achieved by moving towards a collaborative model 
that requires certain changes in thinking and acting 
as counsellors and patients. Both parties must 
acknowledge that learning from each other and 
building shared knowledge in order to achieve an 
appropriate level of relations are indispensable 
steps. We have also introduced the quality indicators 
of Donabedian's model in the process of genetic 
counselling. Quality indicators are an important 
instrument for measuring quality. Their validation is 
needed to enable the feasibility in clinical practice 
and to lead to improved outcomes. The implication 
of science would lead to meaningful quality assur-
ance in the field of genetic counselling, that will 
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S A Ž E T A K  
 
 
Genetsko savetovanje je složen proces koji pomaže ljudima da razumeju i prihvate medicinske, 
psihološke i genetske aspekte bolesti, kao i da donesu odgovarajuću odluku u vezi sa njima. U ovom radu, 
revidirani su svi postojeći modeli za donošenje odluka i predložena je njihova upotreba u procesu genetskog 
savetovanja, što može da dovede do pravičnijih i povoljnijih ishoda. Za procenu kvaliteta u procesu 
genetskog savetovanja primenjen je Donabedijanov model (Struktura–proces–ishod), za razvoj ključnih 
pokazatelja performansi. Predloženi su pokazatelji kvaliteta na „Struktura–proces–ishod” modelu u procesu 
genetskog savetovanja. Takođe, utvrđeni su socijalni, ekonomski i humanistički ishodi. Svi definisani 
indikatori kvaliteta zajedno predstavljaju okvir za praćenje, procenu i kontinuirano unapređenje procesa 
genetskog savetovanja. Iako se nova medicinska usluga genetskog savetovanja razvija, kao snažno 
multidisciplinarno polje, primena modela upravljanja kvalitetom sigurno će doprineti razvoju kolaborativne 
prakse. 
 
Ključne reči: genetsko savetovanje, modeli donošenja odluke, Donabedijanov model, kvalitet 
